News

Metabolic Health Declining Among the Obese, Despite Improvements in BP and Lipids

Author and Disclosure Information

 

FROM THE JOURNAL OF THE AMERICAN HEART ASSOCIATION

References

The study was supported by the Department of Veterans Affairs, the National Institutes of Health, and the University of Alabama Diabetes Research Center.

Dr. Guo had no financial disclosures. Dr. Garvey disclosed relationships with multiple pharmaceutical companies.

Pages

Recommended Reading

Ticagrelor Cuts Post-MI Events in Diabetes Patients
Type 2 Diabetes ICYMI
No rise in serious HF seen in patients taking saxagliptin or sitagliptin
Type 2 Diabetes ICYMI
No Rise in Serious HF Seen in Patients Taking Saxagliptin or Sitagliptin
Type 2 Diabetes ICYMI
VIDEO: Telehealth program cuts cost, hospitalizations for chronic patients
Type 2 Diabetes ICYMI
LEADER: Liraglutide lowers CVD risk in type 2 diabetes
Type 2 Diabetes ICYMI
Menopause and cardiovascular risk examined in type 1 diabetes
Type 2 Diabetes ICYMI
FDA panel narrowly endorses empagliflozin’s cardiovascular mortality benefit
Type 2 Diabetes ICYMI
FDA Panel Narrowly Endorses Empagliflozin’s Cardiovascular Mortality Benefit
Type 2 Diabetes ICYMI
Menopause and Cardiovascular Risk Examined in Type 1 Diabetes
Type 2 Diabetes ICYMI
Statement warns of drugs causing or exacerbating heart failure
Type 2 Diabetes ICYMI